Oral treatment of pernicious anaemia with low doses of H.P.P./1.

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Abstract Text:

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Publishing Authors By Initials

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: azoles: pyrroles: tetrapyrroles: corrinoids: vitamin b 12 research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: azoles: pyrroles: tetrapyrroles: corrinoids: vitamin b 12 research

PUBMED ID PMID:

MEDLINE DATE:

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Lancet

VOLUME: 2

Page Numbers: 291-2

Journal Abbreviation: Lancet

ISSN: 0140-6736

DAY: 6

MONTH: Aug

YEAR: 1960

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985213

Oral treatment of pernicious anaemia with low doses of H.P.P./1. Keywords Mesh Terms:

KEYWORDS: Vitamin B 12

MESH TERMS: therapy

Chemical & Substance for Abstract: Oral treatment of pernicious anaemia with low doses of H.P.P./1. Information

Substance Name: Vitamin B 12

Registry Number: 68-19-9

Grant and Affiliation Information for Oral treatment of pernicious anaemia with low doses of H.P.P./1.

AFFILIATION:

Country: Not Available

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Lancet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Oral treatment of pernicious anaemia with low doses of HPP/1 Related Publications

• An integrated model of choices and response times in absolute identification.
• Antimitochondrial antibody-negative primary biliary cirrhosis.
• Antiviral therapy: chronic hepatitis C.
• Compelling EPR evidence that the alternative oxidase is a diiron carboxylate protein.
• Diagnosis and management of cholestatic liver disease.
• Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
• Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.
• Flavianates of lysine.
• Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
• Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
• Internet access overseas.
• Minimization of the impact of a broad bandwidth high-gain nonlinear preamplifier to the amplified spontaneous emission pedestal of the Vulcan petawatt laser facility.
• Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study.
• Ocular involvement in acute febrile neutrophilic dermatosis (sweet syndrome): new cases and review of the literature.
• Oral treatment of pernicious anaemia with low doses of H.P.P./1.
• Oral treatment of pernicious anaemia: first fifty cases.
• Postgraduate medical training: getting patients on board.
• Preface.
• Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging.
• Primary biliary cirrhosis.
• Primary biliary cirrhosis: the future.
• Recruiting patients for postgraduate medical training in a community family planning clinic: how do patients want to be asked?
• Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.
• Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: Case reports.
• T regulatory cells and autoimmune liver disease.
• The toxicity of small concentrations of cystine to acid-producing bacteria.
• Three atypical cases of Wilson disease: assessment of the Leipzig scoring system in making a diagnosis.
• Toxic effect of the crystals from agenized zein on certain acid-producing bacteria.
• Treatment of hepatitis B: the next five years.
• What motivates patients to become involved in postgraduate medical training in a family planning clinic?